345 related articles for article (PubMed ID: 37478850)
21. Molecular Origin, Expression Regulation, and Biological Function of Androgen Receptor Splicing Variant 7 in Prostate Cancer.
Chen Y; Lan T
Urol Int; 2021; 105(5-6):337-353. PubMed ID: 32957106
[TBL] [Abstract][Full Text] [Related]
22. Novel Strategy of Proxalutamide for the Treatment of Prostate Cancer through Coordinated Blockade of Lipogenesis and Androgen Receptor Axis.
Gu Y; Xue M; Wang Q; Hong X; Wang X; Zhou F; Sun J; Wang G; Peng Y
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948018
[No Abstract] [Full Text] [Related]
23. Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance.
Jamroze A; Chatta G; Tang DG
Cancer Lett; 2021 Oct; 518():1-9. PubMed ID: 34118355
[TBL] [Abstract][Full Text] [Related]
24. Androgen receptor plasticity and its implications for prostate cancer therapy.
Snow O; Lallous N; Singh K; Lack N; Rennie P; Cherkasov A
Cancer Treat Rev; 2019 Dec; 81():101871. PubMed ID: 31698174
[TBL] [Abstract][Full Text] [Related]
25. APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinoma.
Cannataro VL; Kudalkar S; Dasari K; Gaffney SG; Lazowski HM; Jackson LK; Yildiz I; Das RK; Gould Rothberg BE; Anderson KS; Townsend JP
Lung Cancer; 2022 Sep; 171():34-41. PubMed ID: 35872531
[TBL] [Abstract][Full Text] [Related]
26. APOBEC3A is a prominent cytidine deaminase in breast cancer.
Cortez LM; Brown AL; Dennis MA; Collins CD; Brown AJ; Mitchell D; Mertz TM; Roberts SA
PLoS Genet; 2019 Dec; 15(12):e1008545. PubMed ID: 31841499
[TBL] [Abstract][Full Text] [Related]
27. Understanding and targeting prostate cancer cell heterogeneity and plasticity.
Tang DG
Semin Cancer Biol; 2022 Jul; 82():68-93. PubMed ID: 34844845
[TBL] [Abstract][Full Text] [Related]
28. Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer.
Shi MJ; Meng XY; Fontugne J; Chen CL; Radvanyi F; Bernard-Pierrot I
Genome Med; 2020 Sep; 12(1):85. PubMed ID: 32988402
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival.
Li D; Tian G; Wang J; Zhao LY; Co O; Underill ZC; Mymryk JS; Claessens F; Dehm SM; Daaka Y; Liao D
Prostate; 2018 Nov; 78(15):1140-1156. PubMed ID: 30009471
[TBL] [Abstract][Full Text] [Related]
30. The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer.
Liu W; Newhall KP; Khani F; Barlow L; Nguyen D; Gu L; Eng K; Bhinder B; Uppal M; Récapet C; Sboner A; Ross SR; Elemento O; Chelico L; Faltas BM
Cancer Res; 2023 Feb; 83(4):506-520. PubMed ID: 36480186
[TBL] [Abstract][Full Text] [Related]
31. Polyomavirus T Antigen Induces
Starrett GJ; Serebrenik AA; Roelofs PA; McCann JL; Verhalen B; Jarvis MC; Stewart TA; Law EK; Krupp A; Jiang M; Martens JWM; Cahir-McFarland E; Span PN; Harris RS
mBio; 2019 Feb; 10(1):. PubMed ID: 30723127
[TBL] [Abstract][Full Text] [Related]
32. APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses.
DiMarco AV; Qin X; McKinney BJ; Garcia NMG; Van Alsten SC; Mendes EA; Force J; Hanks BA; Troester MA; Owzar K; Xie J; Alvarez JV
Cancer Immunol Res; 2022 Jan; 10(1):70-86. PubMed ID: 34795033
[TBL] [Abstract][Full Text] [Related]
33. Distinct Mutagenic Activity of APOBEC3G Cytidine Deaminase Identified in Bladder Cancer.
Caswell D; Swanton C
Cancer Res; 2023 Feb; 83(4):487-488. PubMed ID: 36789568
[TBL] [Abstract][Full Text] [Related]
34. p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells.
Periyasamy M; Singh AK; Gemma C; Kranjec C; Farzan R; Leach DA; Navaratnam N; Pálinkás HL; Vértessy BG; Fenton TR; Doorbar J; Fuller-Pace F; Meek DW; Coombes RC; Buluwela L; Ali S
Nucleic Acids Res; 2017 Nov; 45(19):11056-11069. PubMed ID: 28977491
[TBL] [Abstract][Full Text] [Related]
35. Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types.
Chen Z; Wen W; Bao J; Kuhs KL; Cai Q; Long J; Shu XO; Zheng W; Guo X
BMC Med Genomics; 2019 Sep; 12(1):131. PubMed ID: 31533728
[TBL] [Abstract][Full Text] [Related]
36. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
[TBL] [Abstract][Full Text] [Related]
37. Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B.
Shi K; Carpenter MA; Banerjee S; Shaban NM; Kurahashi K; Salamango DJ; McCann JL; Starrett GJ; Duffy JV; Demir Ö; Amaro RE; Harki DA; Harris RS; Aihara H
Nat Struct Mol Biol; 2017 Feb; 24(2):131-139. PubMed ID: 27991903
[TBL] [Abstract][Full Text] [Related]
38. APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer.
Wang S; Jia M; He Z; Liu XS
Oncogene; 2018 Jul; 37(29):3924-3936. PubMed ID: 29695832
[TBL] [Abstract][Full Text] [Related]
39. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor.
Mizokami A; Koh E; Fujita H; Maeda Y; Egawa M; Koshida K; Honma S; Keller ET; Namiki M
Cancer Res; 2004 Jan; 64(2):765-71. PubMed ID: 14744796
[TBL] [Abstract][Full Text] [Related]
40. Seleno-aspirin compound AS-10 promotes histone acetylation ahead of suppressing androgen receptor transcription, G1 arrest, and apoptosis of prostate cancer cells.
Karelia DN; Kim S; Plano D; Sharma AK; Jiang C; Lu J
Prostate; 2023 Jan; 83(1):16-29. PubMed ID: 35996318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
